D-0594-2018 Class II Terminated

Recalled by Hetero Labs, Ltd. - Unit III — Hyderabad, N/A

FDA drug recall D-0594-2018 was initiated by Hetero Labs, Ltd. - Unit III on Jan 10, 2018 and is designated Class II. Reason for recall: CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications. The recall status is terminated (terminated Sep 21, 2020). Affected quantity: 3000 bottles.

Recall details

Product Type
Drugs
Report Date
Feb 14, 2018
Initiation Date
Jan 10, 2018
Termination Date
Sep 21, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3000 bottles

Product description

Aripiprazole Tablets, USP, 10 mg, 30-count bottles, Rx Only, Manufactured for Camber Pharmaceuticals, Inc. Piscataway, NJ 08854, By; Hetero Hetero Labs Limited Unit V Polepallly Jadcheria Mahaboob Nagar - 509 301 India, NDC 31722-827-30

Reason for recall

CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.

Distribution pattern

NJ Only

Code information

Lot #: ARI17089, ARI17090, Exp. 5/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0594-2018
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0594-2018. Report a data issue: hello@regdatalab.com.